ArticleJournal of diabetes research2024

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.

Gisle Langslet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.